Unicycive Therapeutics, Inc.
UNCY
$0.6999
$0.0629.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 58.85% | -20.25% | 18.07% | 20.68% | -26.93% |
| Total Depreciation and Amortization | -46.65% | 50.70% | 54.10% | 61.95% | 213.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -186.18% | -32.45% | -127.95% | -119.79% | 22.87% |
| Change in Net Operating Assets | -342.42% | -359.14% | 54.80% | 506.78% | 67.88% |
| Cash from Operations | -49.01% | -56.29% | -32.81% | -13.46% | -25.31% |
| Capital Expenditure | -355.56% | -500.00% | -316.67% | -116.67% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -355.56% | -500.00% | -316.67% | -116.67% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | 65.62% | 65.62% | 65.62% | 65.62% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 90.47% | -69.88% | -49.93% | -48.90% | -58.78% |
| Cash from Financing | -95.72% | 63.71% | 63.22% | 63.30% | 66.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -218.55% | 77.82% | 145.43% | 178.50% | 129.63% |